Mylan is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: 1) the Food and Drug Administration's investigation into the Company's manufacturing plant in Morgantown, West Virginia was the result of whistleblower allegations, and not, as Mylan insinuated, the result of a “regular” inspection; and 2) defendants knew, or were reckless in not knowing that, as a result of Mylan’s continued efforts to remain uncooperative with the Food and Drug Administration, the Morgantown plant would continue to incur substantial setbacks.
If you incurred a loss on MYL stocks purchased between February 16, 2016 and May 7, 2019, this lawsuit is on your behalf. The lawsuit was filed in the the United States District Court for the Western District of Pennsylvania, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until August 25, 2020 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Fill out the form below to be contacted by a representative of Jakubowitz Law.